BP-1-102 is primarily used in research settings as a potent inhibitor of the STAT3 signaling pathway, which plays a key role in cancer progression and immune regulation. It is investigated for its potential in suppressing tumor growth, particularly in cancers where STAT3 is constitutively active, such as breast, lung, and hematological malignancies. Due to its ability to disrupt protein-protein interactions involved in cell survival and proliferation, BP-1-102 serves as a valuable tool compound in oncology and molecular pharmacology studies. Its application supports the development of targeted therapies and helps elucidate the biological functions of STAT3 in disease mechanisms.